IRIS
RONCATO, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.784
AS - Asia 1.294
EU - Europa 625
SA - Sud America 235
AF - Africa 42
OC - Oceania 1
Totale 3.981
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.734
SG - Singapore 644
CN - Cina 273
BR - Brasile 195
HK - Hong Kong 164
IT - Italia 135
RU - Federazione Russa 95
DE - Germania 85
VN - Vietnam 54
IN - India 49
IE - Irlanda 48
GB - Regno Unito 44
KR - Corea 39
FR - Francia 34
FI - Finlandia 33
CA - Canada 26
NL - Olanda 25
AT - Austria 20
MX - Messico 20
UA - Ucraina 20
AR - Argentina 17
CH - Svizzera 16
TG - Togo 15
PL - Polonia 14
SE - Svezia 14
TR - Turchia 14
BD - Bangladesh 12
CZ - Repubblica Ceca 12
ES - Italia 12
ID - Indonesia 7
JP - Giappone 7
ZA - Sudafrica 7
CO - Colombia 5
EC - Ecuador 5
IQ - Iraq 4
LT - Lituania 4
MA - Marocco 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
CL - Cile 3
EG - Egitto 3
KE - Kenya 3
OM - Oman 3
PK - Pakistan 3
RO - Romania 3
SA - Arabia Saudita 3
UY - Uruguay 3
VE - Venezuela 3
AO - Angola 2
CR - Costa Rica 2
DK - Danimarca 2
DZ - Algeria 2
PE - Perù 2
TH - Thailandia 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DM - Dominica 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
KZ - Kazakistan 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 3.981
Salva come PNG Salva come JPEG
Città #
Singapore 260
Ashburn 227
Hong Kong 163
Beijing 122
Chicago 121
Los Angeles 114
Boardman 75
Fairfield 69
Chandler 68
Salt Lake City 57
Dallas 51
Dublin 47
Houston 41
Hefei 40
Munich 40
Seoul 39
Wilmington 39
Woodbridge 38
Cambridge 32
Elk Grove Village 30
Seattle 30
New York 29
Redondo Beach 24
Buffalo 23
Tampa 22
Ho Chi Minh City 19
São Paulo 18
London 17
Hanoi 16
Montreal 16
Zurich 16
Lomé 15
Nuremberg 15
Ann Arbor 14
Miami 14
Santa Clara 14
Dearborn 13
Frankfurt am Main 13
Pune 13
Turku 13
Vienna 13
Ogden 12
Warsaw 12
Denver 11
Brno 10
Genoa 10
Stockholm 10
Amsterdam 9
Helsinki 9
Princeton 9
Sterling 9
Arezzo 8
Brooklyn 8
Chennai 8
Dulles 8
Lappeenranta 8
Milan 8
Redmond 8
Hyderabad 7
Lauterbourg 7
Mumbai 7
Phoenix 7
Tokyo 7
Udine 7
Jacksonville 6
Mexico City 6
Portsmouth 6
Rome 6
Ankara 5
Belluno 5
Belo Horizonte 5
Des Moines 5
Detroit 5
Düsseldorf 5
Guangzhou 5
Guarulhos 5
Lancaster 5
Naples 5
Poplar 5
Rio de Janeiro 5
Boston 4
Brasília 4
Cormons 4
Deiva Marina 4
Izmir 4
Johannesburg 4
Kansas City 4
Las Vegas 4
New Delhi 4
Orem 4
Querétaro 4
Xi'an 4
Zoppola 4
Atlanta 3
Bengaluru 3
Brussels 3
Charlotte 3
Codroipo 3
Cologne 3
Goiânia 3
Totale 2.396
Salva come PNG Salva come JPEG
Nome #
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment 535
Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) 152
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 123
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity 122
The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines 106
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 102
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 100
SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy 95
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 93
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 90
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 88
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients 87
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk 84
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 80
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study 79
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 76
FARMAPRICE: A Pharmacogenetic Clinical decision support system for precise and Cost-Effective Therapy 76
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9) 69
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy 65
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome 63
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 62
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 60
IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm 60
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 60
Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection? 58
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients 58
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 58
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? 57
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 56
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 55
Therapeutic drug monitoring for the cancer patient: challenges and opportunities 54
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer 54
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 53
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer 53
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy 52
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype 51
The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches 51
Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice 51
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach 50
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS) 50
European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology 49
mHealth Apps Available in Italy to Support Health Care Professionals in Antimicrobial Stewardship Implementation: Systematic Search in App Stores and Content Analysis 49
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 49
Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study 47
Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation 47
Genetic biomarkers for hepatocellular cancer risk in a caucasian population 46
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity 46
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 45
Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine 42
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma 42
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 41
Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy 41
Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice 39
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation 38
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI 36
Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients 35
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions 33
Clinical relevance and methodological approach for the assessment of drug–drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) 29
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider 17
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 16
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity – A secondary analysis of the PREPARE trial 12
Totale 4.187
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.568
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.568
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202175 0 0 0 0 0 11 28 11 8 5 7 5
2021/202266 3 5 0 4 2 2 11 0 4 10 14 11
2022/2023318 9 3 4 77 59 70 0 22 45 4 9 16
2023/2024339 31 19 11 4 39 40 21 15 19 31 25 84
2024/20251.233 53 87 42 37 85 69 91 57 126 99 221 266
2025/20261.874 456 408 403 223 320 64 0 0 0 0 0 0
Totale 4.187